Athira Sethu
Kochi, 2 November 2026
Morepen Laboratories has shown impressive financial performance in the second quarter of the financial year 2026-27. Morepen Laboratories registered an increase in revenue by over 81% as the net profit of the company more than doubled from that of the previous year.
The company registered a net profit of ₹89 crore for the quarter of July to September as compared to ₹41 crore last year.
Its total revenue saw a rise of 81.4% from ₹411.6 crore to ₹746.5 crore. It was the second successive quarter for the company wherein it showed its best revenues and profits.
The company also registered a significant rise in its operating profit margin. Its earnings before interest, tax, depreciation, and amortization (EBITDA) registered a rise to ₹123.2 crore from ₹31 crore last year.
The operating profit margin saw a rise to 16.5% from 7.5% during the same quarter last year.
One of the primary drivers behind this growth is the stellar performance in the export segment of the company.
The revenue of the exports saw a rise by 131% to ₹397 crore for the quarter. The medical device segment also did exceptionally well, registering a revenue increase by 65% to ₹208 crore.
CDMO business, which is the contract development and manufacturing of the company, brought revenues worth ₹253 crore. CDMO business deals with the manufacture of medicines and associated products for other pharmaceutical companies.
52% of the combined revenues of the pharmaceutical ingredients business and contract manufacturing business were provided by CDMO.
In the first six months of FY27, total revenue of Morepen Laboratories stood at ₹1,330 crore with an increase of 57% when compared to last year.
Operating profit went up by 243% to ₹220 crore and net profit shot up by 177% to ₹145 crore.
The export revenue more than doubled to ₹654 crore and constituted almost half of the sales of the company.
Currently, Morepen Laboratories is making plans to boost its production capacity in order to grow in the future.
According to Managing Director Sanjay Suri, the company has successfully achieved the first phase of capacity expansion even before time, achieving a capacity level of 614 kilolitres.
Construction has begun for the next phase with an objective of reaching capacity level of 800 kilolitres by Q2 FY28.
At the same time, the company is also concentrating on developing pharmaceutical ingredients, new technology, and collaboration with pharmaceutical companies internationally.
In summary, Morepen Laboratories has achieved good performance in terms of exporting, manufacturing of medical devices, and pharma production.
